Human Genome Sciences
Human Genome Sciences (HGS) was a biopharmaceutical corporation that specialized in the research and development of novel protein and small molecule drugs. The company was founded in 1992 and was based in Rockville, Maryland, United States. In 2012, HGS was acquired by GlaxoSmithKline (GSK), a British multinational pharmaceutical company.
History
HGS was established in 1992 by William A. Haseltine, a renowned scientist in the field of genomics. The company was one of the pioneers in the use of human genome sequencing for drug discovery. In its early years, HGS collaborated with several other companies and academic institutions to identify and patent thousands of human genes.
In 2003, HGS received its first product approval from the Food and Drug Administration (FDA) for Syncria, a drug used for the treatment of Type 2 diabetes. This was followed by the approval of Benlysta, a drug for the treatment of lupus, in 2011.
In 2012, HGS was acquired by GlaxoSmithKline for $3.6 billion. The acquisition was part of GSK's strategy to strengthen its portfolio of innovative pharmaceuticals.
Research and Development
HGS's research and development efforts were focused on the discovery of novel protein and small molecule drugs. The company used a variety of techniques, including genomics, proteomics, and bioinformatics, to identify potential drug targets.
One of the company's most significant achievements was the development of Benlysta, the first new drug for lupus in over 50 years. Benlysta works by inhibiting the activity of B-lymphocyte stimulator (BLyS), a protein that stimulates the production of autoantibodies in lupus patients.
Impact
The work of HGS has had a significant impact on the field of genomics and drug discovery. The company's approach to using human genome sequencing for drug discovery has been adopted by many other biopharmaceutical companies. Furthermore, the development of Benlysta has provided a new treatment option for lupus patients, improving their quality of life.
See Also
References
<references />
This article is a biotechnology stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
